← Back to screener

ARROWHEAD PHARMACEUTICALS, INC. ARWR

Rank #2492 · Nasdaq · $8.4B market cap
Audited by KPMG LLP, no going-concern flag in the latest filing.
Score
13.4
P/E
-41.1
P/B
45.50
ROE
-110.7%
Op. Margin
-85.2%
Debt Ratio
515%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -41.1x, P/B 45.50x. Ranks in the top 82% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -110.7%. Ranks in the top 92% of the universe.

Safety ★☆☆☆☆
Weak

Debt ratio 515%. Ranks in the top 80% of the universe. Above 200% signals meaningful leverage risk.

Growth ★★☆☆☆
Weak

Revenue decline of 1.0% year over year. Ranks in the top 67% of the universe.

Growth is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011$0.0B$-0.0B$-0.0B$0.0B-1969.637
2012$0.0B$-0.0B$-0.0B$0.0B-3319.524
2013$0.0B$-0.0B$-0.0B$0.0B-14358.665
2014$0.0B$-0.0B$-0.0B$0.0B-14358.636
2015$0.0B$-0.0B$-0.0B$0.2B-8471.310
2016$0.0B$-0.1B$-0.1B$0.1B-30443.620
2017$0.0B$-0.1B$-0.1B$0.1B-25124.134
2018$0.0B$-0.1B$-0.1B$0.1B-51627.128
2019$0.0B$-0.0B$-0.0B$0.1B-117.817
2020$0.0B$-0.1B$-0.1B$0.2B-346.543
2021$0.2B$0.1B$0.1B$0.1B36.3449
2022$0.1B$-0.1B$-0.1B$0.4B-105.974
2023$0.1B$-0.1B$-0.1B$0.4B-107.874
2024$0.2B$-0.2B$-0.2B$0.3B-73.4182
2025$0.2B$-0.2B$-0.2B$0.2B-85.2515

← See the full screener